Evidence map›Paper›PMID 35993617›Full record

ArticleInteractive journal of medical research2022

Predicting Therapeutic Response to Unfractionated Heparin Therapy: Machine Learning Approach.

Ahmad Abdel-Hafez, Ian A Scott, Nazanin Falconer, Stephen Canaris, Oscar Bonilla, Sven Marxen, Aaron Van Garderen, Michael Barras

Open access · goldAbstract read
In one paragraph

Article in Interactive journal of medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. [Research progress on perioperative anticoagulants in perioperative period of free flap transplantation].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2025
    Review
  3. Artificial intelligence in clinical thrombosis and hemostasis: A review.Research and practice in thrombosis and haemostasis · 2025
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ahmad Abdel-HafezClinical Informatics, Metro South Health, Queensland Health, Brisbane, Australia.ORCID https://orcid.org/0000-0001-6022-9745
Ian A Scott *Department of Internal Medicine and Clinical Epidemiology, Princess Alexandra Hospital, Brisbane, Australia.ORCID https://orcid.org/0000-0002-7596-0837
Nazanin Falconer *Department of Pharmacy, Princess Alexandra Hospital, Brisbane, Australia.ORCID https://orcid.org/0000-0003-4682-7890
Stephen Canaris *Clinical Informatics, Metro South Health, Queensland Health, Brisbane, Australia.ORCID https://orcid.org/0000-0002-2631-6025
Oscar Bonilla *Clinical Informatics, Metro South Health, Queensland Health, Brisbane, Australia.ORCID https://orcid.org/0000-0001-5598-8560
Sven Marxen *Pharmacy Service, Logan and Beaudesert Hospitals, Logan, Australia.ORCID https://orcid.org/0000-0002-2133-0776
Aaron Van Garderen *Clinical Informatics, Metro South Health, Queensland Health, Brisbane, Australia.ORCID https://orcid.org/0000-0001-6000-612X
Michael Barras *Department of Pharmacy, Princess Alexandra Hospital, Brisbane, Australia.ORCID https://orcid.org/0000-0001-8105-0090
Queensland Health · AUThe University of Queensland · AULogan Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnfractionated heparin (UFH) is an anticoagulant drug that is considered a high-risk medication because an excessive dose can cause bleeding, whereas an insufficient dose can lead to a recurrent embolic event. Therapeutic response to the initiation of intravenous UFH is monitored using activated partial thromboplastin time (aPTT) as a measure of blood clotting time. Clinicians iteratively adjust the dose of UFH toward a target, indication-defined therapeutic aPTT range using nomograms, but this process can be imprecise and can take ≥36 hours to achieve the target range. Thus, a more efficient approach is required.

objectiveIn this study, we aimed to develop and validate a machine learning (ML) algorithm to predict aPTT within 12 hours after a specified bolus and maintenance dose of UFH.

methodsThis was a retrospective cohort study of 3019 patient episodes of care from January 2017 to August 2020 using data collected from electronic health records of 5 hospitals in Queensland, Australia. Data from 4 hospitals were used to build and test ensemble models using cross-validation, whereas data from the fifth hospital were used for external validation. We built 2 ML models: a regression model to predict the aPTT value after a UFH bolus dose and a multiclass model to predict the aPTT, classified as subtherapeutic (aPTT <70 seconds), therapeutic (aPTT 70-100 seconds), or supratherapeutic (aPTT >100 seconds). Modeling was performed using Driverless AI (H2O), an automated ML tool, and 17 different experiments were iteratively conducted to optimize model accuracy.

resultsIn predicting aPTT, the best performing model was an ensemble with 4x LightGBM models with a root mean square error of 31.35 (SD 1.37). In predicting the aPTT class using a repurposed data set, the best performing ensemble model achieved an accuracy of 0.599 (SD 0.0289) and an area under the receiver operating characteristic curve of 0.735. External validation yielded similar results: root mean square error of 30.52 (SD 1.29) for the aPTT prediction model, and accuracy of 0.568 (SD 0.0315) and area under the receiver operating characteristic curve of 0.724 for the aPTT multiclassification model.

conclusionsTo the best of our knowledge, this is the first ML model applied to intravenous UFH dosing that has been developed and externally validated in a multisite adult general medical and surgical inpatient setting. We present the processes of data collection, preparation, and feature engineering for replication.

Indexed as

activated partial thromboplastin timeaPTTheparinmachine learningpersonalized medicinepredictive modeling

Identifiers

PMID35993617
PMCPMC9531006
OpenAlexW4285341019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.